Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
treatment entities : Bristol-myers squibb company save search
European Commission Expands Approval of Bristol Myers Squibb’s Reblozyl® (luspatercept) to Include First-Line Treatment of Transfusion-Dependent Anemia in Adults with Lower-Risk Myelodysplastic Syndromes (LR-MDS)
Published: 2024-04-03 (Crawled : 08:00) - biospace.com/
BMY | $48.86 -0.27% -0.02% 16M
|
Health Technology
|
| O: -0.08%
H: 0.3%
C: -0.99%
reblozyl anemia approval treatment
Bristol Myers Squibb Announces CheckMate -9DW Trial Evaluating Opdivo (nivolumab) Plus Yervoy (ipilimumab) Meets Primary Endpoint of Overall Survival for the First-Line Treatment of Advanced Hepatocellular Carcinoma
Published: 2024-03-20 (Crawled : 12:00) - biospace.com/
BMY | $48.86 -0.27% -0.02% 16M
|
Health Technology
|
| O: -0.33%
H: 1.02%
C: 0.48%
opdivo treatment trial advanced plus
Urinary Tract Infection Treatment Market Projected to Reach US$ 10.73 Billion by 2030: Telemedicine Integration Revolutionizes UTI Care, Self-Care Products Gain Momentum
Published: 2024-02-29 (Crawled : 20:00) - prnewswire.com
GLAXF | News | $19.54 -14.18% 2.6K
|
Health Technology
|
| O: -2.33%
H: 3.68%
C: 2.44%
NVSEF | News | $96.0 6.88% 52K
|
Health Technology
|
| O: 0.89%
H: 0.0%
C: 0.0%
NVS | News | $98.35 1.1% 0.0% 2.2M
|
Health Technology
|
| O: 1.03%
H: 0.14%
C: 0.05%
JNJ | News | $148.53 -0.69% -0.14% 9.6M
|
Health Technology
|
| O: 0.28%
H: 0.0%
C: 0.0%
GSK | News | $40.86 -0.92% -0.15% 1.7M
|
Health Technology
|
| O: 0.26%
H: 0.18%
C: 0.05%
BMY | $48.86 -0.27% -0.02% 16M
|
Health Technology
|
| O: 0.37%
H: 0.27%
C: -0.1%
integration reach momentum infection treatment market
U.S. Food and Drug Administration Accepts for Priority Review Bristol Myers Squibb’s Application for Augtyro™ (repotrectinib) for the Treatment of Patients with NTRK-Positive Locally Advanced or Metastatic Solid Tumors
Published: 2024-02-14 (Crawled : 15:00) - biospace.com/
BMY | $48.86 -0.27% -0.02% 16M
|
Health Technology
|
| O: 0.23%
H: 0.44%
C: 0.14%
drug review food tumors treatment application advanced
Global Epidural Abscess Treatment Market Report 2024 - Treatment Advances and Digital Health Technologies Shaping the Future of Epidural Abscess Care
Published: 2024-02-12 (Crawled : 15:30) - prnewswire.com
AZNCF | News | $140.3 -4.19% 1.5K
|
Health Technology
|
| O: -0.57%
H: 0.04%
C: -1.74%
NVS | News | $98.35 1.1% 0.0% 2.2M
|
Health Technology
|
| O: -1.46%
H: 1.04%
C: 0.97%
LLY | News | $732.2 -1.81% 0.18% 2.1M
|
Health Technology
|
| O: 0.09%
H: 0.0%
C: -0.48%
BMY | $48.86 -0.27% -0.02% 16M
|
Health Technology
|
| O: 0.02%
H: 0.46%
C: -0.14%
ABBV | News | $167.8 -1.03% -0.06% 4.1M
|
Health Technology
|
| O: -0.83%
H: 0.7%
C: -0.27%
ABT | News | $106.89 -0.65% -0.22% 5.1M
|
Health Technology
|
| O: -0.64%
H: 0.0%
C: 0.0%
SNY | News | $46.66 -2.16% -2.21% 1.7M
|
Health Technology
|
| O: -0.86%
H: 0.0%
C: 0.0%
AZN | News | $71.175 0.46% 0.46% 6.1M
|
Health Technology
|
| O: -1.77%
H: 0.46%
C: 0.41%
AMGN | News | $273.085 -0.17% -0.17% 2.5M
|
Health Technology
|
| O: -0.4%
H: 1.6%
C: 1.54%
report health treatment care global market
Global Urinary Tract Infection (UTI) Treatment Market is expected to Reach US$ 13,617.4 million by 2034, rising at a 1.9% CAGR- FMI Study
Published: 2024-01-22 (Crawled : 19:00) - prnewswire.com
GLAXF | News | $19.54 -14.18% 2.6K
|
Health Technology
|
| O: -2.34%
H: 0.43%
C: 0.43%
JNJ | News | $148.53 -0.69% -0.14% 9.6M
|
Health Technology
|
| O: -1.11%
H: 0.0%
C: 0.0%
GSK | News | $40.86 -0.92% -0.15% 1.7M
|
Health Technology
|
| O: -0.76%
H: 0.38%
C: 0.13%
BMY | $48.86 -0.27% -0.02% 16M
|
Health Technology
|
| O: 0.22%
H: 1.49%
C: 0.89%
expected million reach infection treatment global study market
Bristol Myers Squibb Data at ASCO GU 2024 Showcase Transformative Research in the Treatment of Genitourinary Cancers
Published: 2024-01-17 (Crawled : 14:00) - biospace.com/
BMY | $48.86 -0.27% -0.02% 16M
|
Health Technology
|
| O: -0.9%
H: 1.05%
C: 0.87%
asco treatment research
European Medicines Agency Validates Bristol Myers Squibb’s Application for Repotrectinib for the Treatment of Locally Advanced or Metastatic ROS1-Positive Non-Small Cell Lung Cancer and NTRK-Positive Solid Tumors
Published: 2024-01-02 (Crawled : 14:00) - biospace.com/
BMY | $48.86 -0.27% -0.02% 16M
|
Health Technology
|
| O: 0.27%
H: 3.89%
C: 2.55%
lung tumors cancer cell treatment application advanced
Two Early Studies Evaluating Potential First-in-Class CELMoD™ Agent Golcadomide for the Treatment of Non-Hodgkin Lymphomas Presented at ASH 2023
Published: 2023-12-12 (Crawled : 08:00) - biospace.com/
BMY | $48.86 -0.27% -0.02% 16M
|
Health Technology
|
| O: -0.57%
H: 0.28%
C: -0.57%
treatment lymphomas potential
Bristol Myers Squibb Announces Data at ASH 2023 from Diverse Multiple Myeloma Pipeline, Underscoring Range of Tailored Treatment Approaches to Address Unique Patient Needs
Published: 2023-12-12 (Crawled : 08:00) - biospace.com/
BMY | $48.86 -0.27% -0.02% 16M
|
Health Technology
|
| O: -0.57%
H: 0.28%
C: -0.57%
unique treatment
Bristol Myers Squibb Presents New Data at ASH 2023 Demonstrating Clinical Benefit Across B-cell Malignancies with Breyanzi as a Second-Line Treatment in High-Risk Follicular Lymphoma and in Relapsed or Refractory Chronic Lymphocytic Leukemia
Published: 2023-12-11 (Crawled : 08:00) - biospace.com/
BMY | $48.86 -0.27% -0.02% 16M
|
Health Technology
|
| O: 0.42%
H: 1.23%
C: 1.13%
breyanzi treatment leukemia
Mirati Therapeutics Receives Positive Opinion from CHMP for KRAZATI (adagrasib) as a Targeted Treatment Option for Patients with Advanced Non-Small Cell Lung Cancer (NSCLC) with a KRASG12C Mutation Following a Re-Examination Procedure
Published: 2023-11-10 (Crawled : 12:30) - prnewswire.com
BMY | $48.86 -0.27% -0.02% 16M
|
Health Technology
|
| O: 0.4%
H: 0.18%
C: 0.0%
MRTX | $58.7 -0.17% 0.34% 0
|
Health Technology
|
| O: -0.11%
H: 0.0%
C: 0.0%
krasg12 lung chmp positive cancer cell treatment therapeutics
Global HIV Drugs Market Research Report 2023-2031: Long-Acting Injectable HIV Therapies Redefining the Treatment Landscape
Published: 2023-10-02 (Crawled : 17:00) - prnewswire.com
NVS | News | $98.35 1.1% 0.0% 2.2M
|
Health Technology
|
| O: 0.19%
H: 0.03%
C: -0.5%
BMY | $48.86 -0.27% -0.02% 16M
|
Health Technology
|
| O: -0.05%
H: 0.09%
C: -0.28%
SNY | News | $46.66 -2.16% -2.21% 1.7M
|
Health Technology
|
| O: 0.78%
H: 0.0%
C: 0.0%
report treatment research global hiv market
Global Idiopathic Pulmonary Fibrosis (IPF) Treatment Market Projected to Reach $6.17 Billion by 2030: Increasing Prevalence Drives Growth
Published: 2023-09-22 (Crawled : 19:00) - prnewswire.com
NVSEF | News | $96.0 6.88% 52K
|
Health Technology
| Email alert
Add to watchlist
GLPGF | News | $35.5157 71.75% 4.8K
|
Health Technology
| Email alert
Add to watchlist
NVS | News | $98.35 1.1% 0.0% 2.2M
|
Health Technology
| Email alert
Add to watchlist
BMY | $48.86 -0.27% -0.02% 16M
|
Health Technology
| Email alert
Add to watchlist
LMNL | $8.5 0.12% 0.12% 0
|
Health Technology
| Email alert
Add to watchlist
GLPG | News | $28.78 -2.28% -2.33% 140K
|
Health Technology
| Email alert
Add to watchlist
reach treatment fibrosis global growth market
Myasthenia Gravis Treatment Market to Grow Exponentially by 2029 | Brandessence Market Research
Published: 2023-09-18 (Crawled : 14:00) - prnewswire.com
GLAXF | News | $19.54 -14.18% 2.6K
|
Health Technology
|
| O: 2.7%
H: 0.0%
C: -5.11%
GSK | News | $40.86 -0.92% -0.15% 1.7M
|
Health Technology
|
| O: 0.72%
H: 0.13%
C: -0.93%
BMY | $48.86 -0.27% -0.02% 16M
|
Health Technology
|
| O: 0.02%
H: 0.18%
C: -0.78%
ABBV | News | $167.8 -1.03% -0.06% 4.1M
|
Health Technology
|
| O: 0.33%
H: 0.0%
C: 0.0%
BIIB | $201.91 4.52% 4.32% 3.3M
|
Health Technology
|
| O: 0.06%
H: 0.44%
C: -0.64%
treatment research market
Six-Year Outcomes from Phase 3 CheckMate -227 Trial Show Durable, Long-Term Survival with Opdivo (nivolumab) Plus Yervoy (ipilimumab) in the First-Line Treatment of Patients with Metastatic Non-Small Cell Lung Cancer
Published: 2023-09-11 (Crawled : 14:00) - biospace.com/
BMY | $48.86 -0.27% -0.02% 16M
|
Health Technology
|
| O: -0.12%
H: 1.11%
C: 0.1%
lung opdivo cancer cell treatment trial plus show
U.S. FDA Approves Bristol Myers Squibb’s Reblozyl® (luspatercept-aamt) as First-Line Treatment of Anemia in Adults with Lower-Risk Myelodysplastic Syndromes (MDS) Who May Require Transfusions
Published: 2023-08-29 (Crawled : 07:00) - biospace.com/
BMY | $48.86 -0.27% -0.02% 16M
|
Health Technology
|
| O: 0.55%
H: 2.31%
C: 1.4%
reblozyl fda anemia treatment
Global Hemorrhagic Shock Treatment Market Projected to Expand at a CAGR of 4.4%, Reaching $279.5 Million by 2030
Published: 2023-08-25 (Crawled : 19:00) - prnewswire.com
NVS | News | $98.35 1.1% 0.0% 2.2M
|
Health Technology
| Email alert
Add to watchlist
JNJ | News | $148.53 -0.69% -0.14% 9.6M
|
Health Technology
| Email alert
Add to watchlist
NVSEF | News | $96.0 6.88% 52K
|
Health Technology
| Email alert
Add to watchlist
BMY | $48.86 -0.27% -0.02% 16M
|
Health Technology
| Email alert
Add to watchlist
TEVJF | News | $12.37 -24.22% 380
|
Health Technology
| Email alert
Add to watchlist
treatment global market
Bristol Myers Squibb Receives Positive CHMP Opinion Recommending Approval for Opdivo (nivolumab) as an Adjuvant Treatment for Patients with Completely Resected Stage IIB or IIC Melanoma
Published: 2023-07-21 (Crawled : 12:20) - biospace.com/
BMY | $48.86 -0.27% -0.02% 16M
|
Health Technology
|
| O: 0.19%
H: 1.41%
C: 1.24%
melanoma chmp opdivo approval positive treatment
Ayala Pharmaceuticals Announces Successful End-of-Phase 2 Meeting with FDA Regarding AL102 for the Treatment of Desmoid Tumors
Published: 2023-07-05 (Crawled : 12:00) - globenewswire.com
BMY | $48.86 -0.27% -0.02% 16M
|
Health Technology
|
| O: -0.19%
H: 1.07%
C: 0.65%
ADXS | $0.54 12.48% 950
|
Health Technology
|
| O: 1.24%
H: 0.0%
C: -7.09%
al102 fda tumors treatment pharmaceuticals meeting phase 2
Gainers vs Losers
| 62% | 38% |
Top 10 Gainers
CSSE 4 | $0.4323 183.85% 64.77% 220M
|
Consumer Services
BOF | $1.99 70.09% 41.21% 110M
|
ILAG | $0.51 6.03% 40.62% 1.7M
|
LICN | $0.941 68.04% 40.49% 15M
|
AMST | $3.31 65.5% 39.58% 70M
|
Technology Services
MTC | $3.615 61.38% 38.04% 9.3M
|
Technology Services
WIMI | $1.15 58.53% 36.92% 19M
|
Technology Services
AIH | $0.45 12.5% 30.92% 320K
|
Health Services
MULN | News | $3.78 38.46% 27.78% 13M
|
Information
RILY | $29.86 37.48% 27.26% 12M
|
Finance
Your saved searches
Save your searches and get alerts when important news are released.